NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $94,313 | -98.0% | 23,116 | -93.6% | 0.00% | -100.0% |
| Q3 2022 | $4,747,000 | -72.0% | 362,900 | -72.5% | 0.02% | -73.2% |
| Q2 2022 | $16,931,000 | -65.4% | 1,320,662 | -58.9% | 0.07% | -63.4% |
| Q1 2022 | $48,966,000 | -16.2% | 3,210,871 | -2.6% | 0.19% | -16.7% |
| Q4 2021 | $58,406,000 | +92.6% | 3,297,898 | +128.5% | 0.23% | +75.2% |
| Q3 2021 | $30,332,000 | +78.0% | 1,442,994 | +67.0% | 0.13% | +72.7% |
| Q2 2021 | $17,042,000 | -73.0% | 864,200 | -60.3% | 0.08% | -73.9% |
| Q1 2021 | $63,227,000 | +18.5% | 2,175,000 | +23.5% | 0.30% | +13.5% |
| Q4 2020 | $53,354,000 | +108.0% | 1,761,157 | +9.3% | 0.26% | +98.5% |
| Q3 2020 | $25,645,000 | -14.7% | 1,611,850 | +5.8% | 0.13% | -33.2% |
| Q2 2020 | $30,076,000 | +144.8% | 1,523,585 | +52.9% | 0.20% | +96.0% |
| Q1 2020 | $12,284,000 | – | 996,295 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |